G6PD and atherosclerosis: To investigate the relative contribution of the PPP to key monocyte and macrophage functions during atherosclerosis we used DHEA, a pharmacological inhibitor targeting glucose-6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme controlling metabolic flux into this pathway (Fig. S8C).